The European Food Safety Authority (EFSA) panel has concluded BioExx Specialty Proteins’ scientific opinion on the safety of Isolexx rapeseed (canola) protein isolate as a novel food ingredient.
The panel observed that the biological value of rapeseed and soy protein, observed by the protein digestibility corrected amino acid score (PDCAAS), appears to be similar.
In studies with rats, the panel observed absence of toxicologically relevant effects of Isolexx and noted the source and nature of the novel food.
The panel, however, found that rapeseed protein could trigger an allergic reaction in mustard allergic subjects and accepted that Isolexx is safe under the proposed conditions of use.
The European Commission should draft the implementing decision to authorize rapeseed protein to be placed on the market as a novel food ingredient in the EU.
BioExx expects the approval of EU nations over the next three to four months.
In addition, the company has completed the initial steps of the sales process, including canvassing approximately 100 potentially interested parties throughout North America and Europe.
The company has set 15 November as a deadline for receiving bids from interested parties.
